Referred to the Committee on Small Business, and in addition to the Committee on Science, Space, and Technology, for a period to be subsequently determined by the Speaker, in each…
This bill amends section 9 of the Small Business Act to extend and expand several SBIR/STTR pilot authorities through fiscal year 2030. It broadens which federal agencies may use the direct to Phase II authority (previously cited examples expanded to any federal agency required to carry out an SBIR program), updates program end dates from 2025 to 2030 for multiple pilot efforts (including a civilian agencies commercialization readiness pilot, Phase 0 proof-of-concept partnerships, and commercialization assistance pilots), and adds limits and reporting requirements for direct to Phase II awards (a 10 percent cap on a given agency's SBIR program funding, 15 percent for NIH, and a requirement to report number and amounts of awards).
Scope of agency authority: liberals and centrists view broader agency participation as an opportunity for civilian priorities, while conservatives worry about federal overreach and 'picking winners.'
Relative to its intended legislative type, this bill is a focused statutory amendment package that extends several SBIR/STTR pilot authorities, broadens which agencies may use direct-to-Phase II authority, imposes percentage limits (with a higher cap for NIH), and adds a reporting requirement tied to an existing statutorily required report.
This bill amends section 9 of the Small Business Act to extend and expand several SBIR/STTR pilot authorities through fiscal year 2030.
It broadens which federal agencies may use the direct to Phase II authority (previously cited examples expanded to any federal agency required to carry out an SBIR program), updates program end dates from 2025 to 2030 for multiple pilot efforts (including a civilian agencies commercialization readiness pilot, Phase 0 proof-of-concept partnerships, and commercialization assistance pilots), and adds limits and reporting requirements for direct to Phase II awards (a 10 percent cap on a given agency's SBIR program funding, 15 percent for NIH, and a requirement to report number and amounts of awards).
The bill leaves base SBIR/STTR funding levels unchanged but changes allowable uses and oversight/expiration dates for specified pilot authorities.
On content alone, the bill is a routine, narrowly tailored extension and modest expansion of existing SBIR/STTR authorities that includes oversight safeguards (caps and reporting) and preserves a sunset approach. Such technical fixes for federal research commercialization programs commonly clear Congress with bipartisan support and low controversy. The main barriers would be timing, legislative vehicle choices, or procedural hurdles rather than substantive opposition.
Relative to its intended legislative type, this bill is a focused statutory amendment package that extends several SBIR/STTR pilot authorities, broadens which agencies may use direct-to-Phase II authority, imposes percentage limits (with a higher cap for NIH), and adds a reporting requirement tied to an existing statutorily required report.
Scope of agency authority: liberals and centrists view broader agency participation as an opportunity for civilian priorities, while conservatives worry about federal overreach and 'picking winners.'
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope of agency authority: liberals and centrists view broader agency participation as an opportunity for civilian priorities, while conservatives worry about federal overreach and 'picking winners.'
A mainstream progressive would likely view this bill positively overall because it extends programs that support early-stage small businesses and technology commercialization, and it adds reporting and caps that increase accountability.
They would welcome broader agency participation (beyond DoD, NIH, and Education) if it helps bring public-interest innovations (health, clean energy, climate resilience) to market.
However, they may want stronger equity, transparency, and public-interest safeguards to ensure benefits reach underrepresented entrepreneurs and align with climate and social goals.
A pragmatic moderate would likely be cautiously supportive.
The bill extends useful small-business R&D tools and includes sensible safeguards (a numerical cap and a reporting requirement) that help control scope and improve oversight.
They would want clear data demonstrating pilots’ effectiveness and careful fiscal management, and may push for periodic review to justify making pilots permanent.
A mainstream conservative would have a mixed response.
They may appreciate continued support for small-business innovation and the explicit caps, but be wary of expanding authority to more federal agencies (which could be seen as expanding federal intervention and the government ‘picking winners’).
Concerns would focus on potential mission creep, lack of tight fiscal controls beyond the percentage cap, and additional administrative or regulatory burdens.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a routine, narrowly tailored extension and modest expansion of existing SBIR/STTR authorities that includes oversight safeguards (caps and reporting) and preserves a sunset approach. Such technical fixes for federal research commercialization programs commonly clear Congress with bipartisan support and low controversy. The main barriers would be timing, legislative vehicle choices, or procedural hurdles rather than substantive opposition.
The bill has not accumulated any surfaced votes yet.
Scope of agency authority: liberals and centrists view broader agency participation as an opportunity for civilian priorities, while conser…
On content alone, the bill is a routine, narrowly tailored extension and modest expansion of existing SBIR/STTR authorities that includes o…
Relative to its intended legislative type, this bill is a focused statutory amendment package that extends several SBIR/STTR pilot authorities, broadens which agencies may use direct-to-Phase II authority, imposes perce…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.